Excerpts

In addition, both genes showed similar trends in different stages, with a clear trend of increasing PDL1 scores in stage IV and stage II–III, and an increasing trend of ACSS2 scores in stage I and stage II–III ( Figure 5 g,j).

The results of this study showed a decreasing trend of immune checkpoint expression (PD-1, PD-L1, PD-L2, TIM-3, LAG-3 and galectin-9) in two of the three cell lines when treated with cisplatin, oxaliplatin or pemetrexed [ 128 ].

Findings suggest (1) a positive trend between the diagnostic performance and radiologist’s experience, (2) DNN yielded equivalent or even higher performance in comparison with senior radiologists, and (3) low image resolution reduced the model performance in predicting the risks of GGNs.

LY3009120 increased the percentage of early apoptotic cells to 15%, and LY3009120 plus hydroxyurea induced a highly significant induction of 35% early apoptosis after 24 h ( Figure 2 b).

All but one of the associations remained nominally significant in regression models adjusted with various confounding factors.

However, we observed a highly significant positive correlation between ELN expression and the expression of EMT markers, including VIM, SNAI1, and TWIST.

Moreover, there was a strong trend for a prediction of death during the first 3 months.

With a mean change difference of 4.5 points between arms (very close to the MCID criterion of ≥5 points), overall satisfaction showed a trend towards a clinically meaningful impact in the intervention arm.

Introduction Breast cancer is the most frequent cancer among women, and its incidence shows an increasing trend, while its mortality is slightly decreasing, although it is still the highest of all cancers in women.

Prevalence of genotypes 16, 18, 59, 66, and 68 increased at three to nine months from baseline both in single and multiple infections, whereas genotypes 31, 33, 35, and 45 showed a decreasing trend.

Final data from this phase II clinical trial reported a positive trend in mean overall survival (mOS) for patients treated with neoadjuvant GVAX alone (35.0 months compared to 24.8 months in historical controls) in comparison with patients who were additionally treated with cyclophosphamide (mOS 15.4 and 16.5 months) [ 29 ].

The incidence of D-NETs has shown an increasing trend from 0.027/100,000 in 1983 to 1.1/100,000 in 2010 [ 3 ] paralleling the increasing volume of upper GI endoscopies [ 4 ].

Interestingly, a decreasing trend of the performance against the number of samples (lesions) used for testing the AI model was noticed as shown in Figure 1 .

This study showed a strong trend towards higher GLS protein expression in the high proliferative ER+ tumours in invasive breast cancer and in DCIS.

A borderline significance was observed for age: young patients (<55 years) were more favorable to be in P4 (24.2%) compared with the elderly (≥75 years) who were allocated in P1 (25.9%) ( p = 0.055).

By fitting the M1-M7 signatures to the BABE data, the discriminatory performance of 5 signatures was confirmed (in terms of AUC value) but borderline significant for the remaining 2 ( Figure 3 ).

Especially striking is the highly significant increased proportion of patients with respiratory failure who require stronger oxygen support in the G-CSF group.

In terms of TFR, ELTS score had a weak trend in predicting successful TFR [ 89 ]. 5.7.

There was a nonsignificant trend for inferior outcomes with increased preceding therapy lines.

However, there may be significant value in diagnostic tests that affect the Bayesian probability of cancer, regardless of underlying genetics.

Our in vivo results revealed that lung metastasis rate was lower in mice injected with CD44-knockdowned lung cancer cells, although the p -value was only borderline significant from statistical analysis.

Assessment of AFIR in different BCCs and SCCs histological subtypes showed a trend to decline not statistically significantly but directly proportional to tumor thickness and infiltration.

The memantine cotreatment had a nonsignificant trend in increasing the BrdU-immunopositive cell count when compared with that in the paclitaxel treatment group.

Furthermore, no evidence for any association between these variants in MMR genes and breast cancer has been seen in larger case control studies [ 1 ], segregation analysis [ 23 ], nor in prospective analysis of PV carriers [ 24 ], with the possible exception of MSH6 in BRIDGES, which was borderline significant at two-fold risk [ 16 ].

Conversely, we know that other studies showed a negative trend over the years in the incidence of endometriotic disease [ 97 , 98 ].